Literature DB >> 32851373

Association of Interstitial Lung Disease With Clinical Characteristics of Chinese Patients With Systemic Lupus Erythematosus.

Yaling Chen1, Yanqing Wang1, Xiangfang Chen1, Huishun Liang2, Xuwei Yang1.   

Abstract

OBJECTIVES: This study aims to evaluate the frequency and clinical and laboratory features of interstitial lung disease (ILD) in Chinese patients with systemic lupus erythematosus (SLE) and to evaluate the association of ILD with the clinical features. PATIENTS AND METHODS: The study included 505 SLE patients (64 males, 441 females; mean age 35.3±15.3 years; range, 14 to 87 years) who were categorized into two groups as 449 patients without ILD and 56 patients with ILD based on evidence obtained from high-resolution computed tomography images. The demographic data, clinical and laboratory findings, SLE disease activity index score, and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index of all patients were also recorded and statistically analyzed.
RESULTS: The ILD frequency in patients with SLE was 11.1%. Compared to the group of SLE patients without ILD, the group of SLE patients with ILD possessed the following statistical differences: elderly age, longer illness duration, lower level of anti-double-stranded deoxyribonucleic acid, and higher level of serum complement 3, increased ratios of Raynaud's phenomenon, moist rales and tachypnea. Multivariate logistic regression results suggested that elderly age (≥60 years), long illness duration (1-10 years, ≥10 years), Raynaud's phenomenon, and tachypnea were statistically associated with the occurrence of ILD in SLE patients.
CONCLUSION: Chinese SLE patients who possessed the factors that were statistically associated with ILD, namely, elderly age (≥60 years old), long illness duration (≥1 years), Raynaud's phenomenon, and tachypnea, were recommended to be monitored for the possibility of ILD.
Copyright © 2020, Turkish League Against Rheumatism.

Entities:  

Keywords:  Interstitial lung disease; systemic lupus erythematosus

Year:  2020        PMID: 32851373      PMCID: PMC7406170          DOI: 10.46497/ArchRheumatol.2020.7583

Source DB:  PubMed          Journal:  Arch Rheumatol        ISSN: 2148-5046            Impact factor:   1.472


  40 in total

Review 1.  Late-onset systemic lupus erythematosus: epidemiology, diagnosis and treatment.

Authors:  Laurent Arnaud; Alexis Mathian; Jacques Boddaert; Zahir Amoura
Journal:  Drugs Aging       Date:  2012-03-01       Impact factor: 3.923

2.  Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival.

Authors:  K R Flaherty; G B Toews; J P Lynch; E A Kazerooni; B H Gross; R L Strawderman; K Hariharan; A Flint; F J Martinez
Journal:  Am J Med       Date:  2001-03       Impact factor: 4.965

3.  Connective tissue disease-associated interstitial lung disease: a call for clarification.

Authors:  Aryeh Fischer; Sterling G West; Jeffrey J Swigris; Kevin K Brown; Roland M du Bois
Journal:  Chest       Date:  2010-08       Impact factor: 9.410

Review 4.  Cyclophosphamide for connective tissue disease-associated interstitial lung disease.

Authors:  Hayley Barnes; Anne E Holland; Glen P Westall; Nicole Sl Goh; Ian N Glaspole
Journal:  Cochrane Database Syst Rev       Date:  2018-01-03

5.  Pulmonary manifestations in late versus early systemic lupus erythematosus: A systematic review and meta-analysis.

Authors:  Jennifer L Medlin; Karen E Hansen; Sara S McCoy; Christie M Bartels
Journal:  Semin Arthritis Rheum       Date:  2018-01-31       Impact factor: 5.532

6.  Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus.

Authors:  R Cervera; M A Khamashta; J Font; G D Sebastiani; A Gil; P Lavilla; I Doménech; A O Aydintug; A Jedryka-Góral; E de Ramón
Journal:  Medicine (Baltimore)       Date:  1993-03       Impact factor: 1.889

7.  Bronchiolitis obliterans organizing pneumonia associated with systemic lupus erythematosus.

Authors:  R B Gammon; T A Bridges; H al-Nezir; C B Alexander; J I Kennedy
Journal:  Chest       Date:  1992-10       Impact factor: 9.410

8.  Desquamative interstitial pneumonitis in a patient with systemic lupus erythematosus.

Authors:  Faranak Esmaeilbeigi; Stephen Juvet; David Hwang; Shikha Mittoo
Journal:  Can Respir J       Date:  2012 Jan-Feb       Impact factor: 2.409

9.  Sequential changes of serum KL-6 predict the progression of interstitial lung disease.

Authors:  Ying Jiang; Qun Luo; Qian Han; Junting Huang; Yonger Ou; Miao Chen; Yu Wen; Silas Sethiel Mosha; Kuimiao Deng; Rongchang Chen
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

10.  Bronchoalveolar lavage fluid and serum canine surfactant protein A concentrations in dogs with chronic cough by bronchial and interstitial lung diseases.

Authors:  Yoshiki Yamaya; Kazuyuki Suzuki; Toshihiro Watari; Ryuji Asano
Journal:  J Vet Med Sci       Date:  2013-12-20       Impact factor: 1.267

View more
  2 in total

1.  Epidemiology of interstitial lung disease in systemic lupus erythematosus in France: A nation-wide population-based study over 10 years.

Authors:  Arthur Mageau; Raphaël Borie; Bruno Crestani; Jean-François Timsit; Thomas Papo; Karim Sacre
Journal:  Respirology       Date:  2022-04-21       Impact factor: 6.175

Review 2.  Respiratory Manifestations in Systemic Lupus Erythematosus.

Authors:  Salvatore Di Bartolomeo; Alessia Alunno; Francesco Carubbi
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.